Previous 10 | Next 10 |
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fires...
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upc...
Checkpoint Therapeutics (NASDAQ:CKPT): Q2 GAAP EPS of -$0.12 misses by $0.02. Revenue of $0.16M (+300.0% Y/Y) beats by $0.05M. Press Release For further details see: Checkpoint Therapeutics EPS misses by $0.02, beats on revenue
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2021. James F. Oliviero, Preside...
Checkpoint Therapeutics expects to report Cosibelimab’s top-line data in Q4 of this year. The company anticipates submitting a BLA and MMA next year with a potential launch in 2023. I have pushed CKPT aside several times, but I can no longer ignore its potential upside from Cos...
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the Ladenburg ...
One very big stock market winner on Wednesday was Checkpoint Therapeutics (NASDAQ: CKPT) . Shares of the company zoomed 19% higher after glowing coverage on its stock was initiated by an analyst. B. Riley Securities prognosticator Justin Walsh is bullish on Checkpoint. Actually,...
primeimages/E+ via Getty Images B. Riley analyst Justin Walsh is so bullish on shares of Checkpoint Therapeutics (CKPT) that his price target of $18 per share represents upside of more than 567% from yesterday's closing price. Shares are up 24.1% to $3.30 in afternoon trading. Walsh...
Gainers: Aethlon Medical AEMD +425%, Checkpoint Therapeutics CKPT +26%, Adamis Pharmaceuticals ADMP +12%, SCWorx (WORX) +18%, ZIOPHARM Oncology ZIOP +15%.Losers: Atossa Therapeutics ATOS -14%, CEL-SCI CVM -11%, Precipio (PR...
Aethlon Medical (AEMD) +280% after publication of its case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®.Checkpoint Therapeutics (CKPT) +50%.Antelope Enterprise Holdings Limited (AEHL) +45%.SPI Energy (SPI) +41% as its group Company is build...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...